Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (112)

Advertisement

Research Article Free access | 10.1172/JCI116644

Modulation of cholinergic neural bronchoconstriction by endogenous nitric oxide and vasoactive intestinal peptide in human airways in vitro.

J K Ward, M G Belvisi, A J Fox, M Miura, S Tadjkarimi, M H Yacoub, and P J Barnes

Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London, United Kingdom.

Find articles by Ward, J. in: PubMed | Google Scholar

Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London, United Kingdom.

Find articles by Belvisi, M. in: PubMed | Google Scholar

Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London, United Kingdom.

Find articles by Fox, A. in: PubMed | Google Scholar

Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London, United Kingdom.

Find articles by Miura, M. in: PubMed | Google Scholar

Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London, United Kingdom.

Find articles by Tadjkarimi, S. in: PubMed | Google Scholar

Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London, United Kingdom.

Find articles by Yacoub, M. in: PubMed | Google Scholar

Department of Thoracic Medicine, Royal Brompton National Heart and Lung Institute, London, United Kingdom.

Find articles by Barnes, P. in: PubMed | Google Scholar

Published August 1, 1993 - More info

Published in Volume 92, Issue 2 on August 1, 1993
J Clin Invest. 1993;92(2):736–742. https://doi.org/10.1172/JCI116644.
© 1993 The American Society for Clinical Investigation
Published August 1, 1993 - Version history
View PDF
Abstract

Human airway smooth muscle possesses an inhibitory nonadrenergic noncholinergic neural bronchodilator response mediated by nitric oxide (NO). In guinea pig trachea both endogenous NO and vasoactive intestinal peptide (VIP) modulate cholinergic neural contractile responses. To identify whether endogenous NO or VIP can modulate cholinergic contractile responses in human airways in vitro, we studied the effects of specific NO synthase inhibitors and the peptidase alpha-chymotrypsin on contractile responses evoked by electrical field stimulation (EFS) at three airway levels. Endogenous NO, but not VIP, was shown to inhibit cholinergic contractile responses at all airway levels but this inhibition was predominantly in trachea and main bronchus and less marked in segmental and subsegmental bronchi. To elucidate the mechanism of this modulation we then studied the effects of endogenous NO on acetylcholine (ACh) release evoked by EFS from tracheal smooth muscle strips. We confirmed that release was neural in origin, frequency dependent, and that endogenous NO did not affect ACh release. These findings show that endogenous NO, but not VIP, evoked by EFS can inhibit cholinergic neural responses via functional antagonism of ACh at the airway smooth muscle and that the contribution of this modulation is less marked in lower airways.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 736
page 736
icon of scanned page 737
page 737
icon of scanned page 738
page 738
icon of scanned page 739
page 739
icon of scanned page 740
page 740
icon of scanned page 741
page 741
icon of scanned page 742
page 742
Version history
  • Version 1 (August 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (112)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts